Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome

Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maint...

Descripción completa

Detalles Bibliográficos
Autores principales: Oka, Satoko, Ono, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222761/
https://www.ncbi.nlm.nih.gov/pubmed/34194792
http://dx.doi.org/10.1002/ccr3.4287
_version_ 1783711556129783808
author Oka, Satoko
Ono, Kazuo
author_facet Oka, Satoko
Ono, Kazuo
author_sort Oka, Satoko
collection PubMed
description Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib.
format Online
Article
Text
id pubmed-8222761
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82227612021-06-29 Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome Oka, Satoko Ono, Kazuo Clin Case Rep Case Reports Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib. John Wiley and Sons Inc. 2021-06-23 /pmc/articles/PMC8222761/ /pubmed/34194792 http://dx.doi.org/10.1002/ccr3.4287 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Oka, Satoko
Ono, Kazuo
Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
title Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
title_full Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
title_fullStr Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
title_full_unstemmed Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
title_short Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
title_sort successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222761/
https://www.ncbi.nlm.nih.gov/pubmed/34194792
http://dx.doi.org/10.1002/ccr3.4287
work_keys_str_mv AT okasatoko successfulixazomibtreatmentforrelapsedandrefractoryacutemyeloidleukemiatransformedfrommyelodysplasticsyndrome
AT onokazuo successfulixazomibtreatmentforrelapsedandrefractoryacutemyeloidleukemiatransformedfrommyelodysplasticsyndrome

Ejemplares similares